Sugi Predict

Sugi Predict / Targets / ELAVL1

ELAVL1

ELAV-like protein 1 · Q15717 · ELAVL1 on Sugi Atlas →

2,291 patent compounds predicted against ELAVL1, 1,520 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1156321 SCHEMBL1156321 0.45 5/20
SCHEMBL1156697 SCHEMBL1156697 0.42 4/20
SCHEMBL3044328 SCHEMBL3044328 0.51 3/20
SCHEMBL1156235 SCHEMBL1156235 0.38 3/20
SCHEMBL4312603 SCHEMBL4312603 0.55 2/20
SCHEMBL3548045 SCHEMBL3548045 0.45 2/20
SCHEMBL1156459 SCHEMBL1156459 0.43 2/20
SCHEMBL1156669 SCHEMBL1156669 0.40 2/20
SCHEMBL2995288 SCHEMBL2995288 0.38 2/20
SCHEMBL1156208 SCHEMBL1156208 0.37 2/20
SCHEMBL10949125 SCHEMBL10949125 0.34 2/20
SCHEMBL5802131 SCHEMBL5802131 0.33 2/20
SCHEMBL11793572 SCHEMBL11793572 0.33 2/20
SCHEMBL10941056 SCHEMBL10941056 0.32 2/20
Dihydrotanshinone I Dihydrotanshinone I (SCHEMBL5940466) 1.00 1/20
SCHEMBL7814270 SCHEMBL7814270 1.00 1/20
SCHEMBL9189649 SCHEMBL9189649 0.85 1/20
SCHEMBL9612283 SCHEMBL9612283 0.83 1/20
SCHEMBL866958 SCHEMBL866958 0.82 1/20
Ammonia Solution, Strong Ammonia Solution, Strong (SCHEMBL7551968) 0.80 1/20

Clinical trials — most relevant to ELAVL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome PHASE2COMPLETED
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) PHASE1COMPLETED
The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients nanUNKNOWN
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank nanCOMPLETED
Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis nanCOMPLETED
Novel Biophotonics Methodology for Colon Cancer Screening nanCOMPLETED
Identification of Novel Bio-markers for Environmental Enteropathy in Children Using an Evidence Based Approach nanCOMPLETED
miR-142-3p as Potential Biomarker of Synaptopathy in MS nanUNKNOWN
Exosomal microRNAs as a Biomarker in Panic Disorder and in Response to CBT nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia nanRECRUITING
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma nanCOMPLETED
Role of Specific microRNAs in Cluster Headache nanRECRUITING
Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker) nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage nanUNKNOWN
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
APAP Hepatotoxicity After Therapeutic Doses nanUNKNOWN
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy nanCOMPLETED
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain nanCOMPLETED
The EPigenetic Consequences in Children of Intravenous vs Volatile Anaesthesia for Surgery (EPIVA) nanACTIVE_NOT_RECRUITING
Identification of New FTLD Genes nanUNKNOWN
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures nanRECRUITING
Study of Specimens From Young Patients With Neuroblastoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ELAVL1 binder may also engage these)

ProteinNameSimilarity
B5DF91 — 0.997 B5DF91 →
Q5U259 — 0.997 Q5U259 →
Q6GLB5 — 0.996 Q6GLB5 →
P70372 — 0.996 P70372 →
Q1JQ73 — 0.995 Q1JQ73 →
Q28FX0 — 0.988 Q28FX0 →
Q8CH84 — 0.987 Q8CH84 →
Q60899 — 0.987 Q60899 →
Q91584 — 0.986 Q91584 →
Q5R9Z6 — 0.985 Q5R9Z6 →
Q28GD4 — 0.984 Q28GD4 →
P26378 — 0.984 P26378 →
Q12926 — 0.982 Q12926 →
Q60900 — 0.982 Q60900 →
Q61701 — 0.982 Q61701 →
O09032 — 0.982 O09032 →
ELAVL3 ELAV-like protein 3 0.982 landscape →
Q91903 — 0.979 Q91903 →
A4QNI8 — 0.978 A4QNI8 →
Q7SZT7 — 0.977 Q7SZT7 →
A0A0R4IEW8 — 0.969 A0A0R4IEW8 →
Q8BHN5 — 0.967 Q8BHN5 →
Q8CFD1 — 0.966 Q8CFD1 →
Q8IUH3 — 0.965 Q8IUH3 →
Q9M427 — 0.960 Q9M427 →
Q9LQI9 — 0.960 Q9LQI9 →
O17310 — 0.958 O17310 →
Q1RMJ7 — 0.958 Q1RMJ7 →
O97018 — 0.958 O97018 →
Q8WN55 — 0.958 Q8WN55 →